Linked Life Data

8542165

Source:http://linkedlifedata.com/resource/pubmed/id/8542165

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1996-2-13
pubmed:abstractText
Regular monotherapy with inhaled beta 2-agonists may lead to a temporary increase of airway obstruction and increase of airway responsiveness after cessation of treatment. We investigated whether anti-inflammatory therapy may affect these rebound phenomena. In a double-blind, placebo-controlled study, we assessed lung function (FEV1) and airway responsiveness (PC20 methacholine [PC20]) during and after cessation of 2 wk of regular treatment with placebo and low-dose (250 micrograms) and high-dose (1,000 micrograms) inhaled terbutaline three times daily. Patients with mild allergic asthma (means [+/- SD] age of 28.2 +/- 6.6 yr, mean FEV1% of 91.9 +/- 14.6%, and geometric mean PC20 of 0.25 mg/ml) were studied. One group (n = 16) was randomized to budesonide treatment, 400 micrograms three times daily; the other group (n = 14) to placebo. PC20 and FEV1 were measured 10, 14, 34, and 82 h after the last terbutaline or placebo inhalation. A different method of statistical analysis was used, in that measurements performed at 10, 14, and 34 h were expressed relative to 82 h values in each period as an area-under-the-curve (AUC) value. FEV1 did not significantly change during placebo and budesonide treatment. Mean PC20 and morning and evening peak expiratory flow were significantly higher during budesonide treatment (p < 0.01). PC20 did not significantly change after cessation of terbutaline treatment in both placebo and budesonide treatment groups. AUC-FEV1 values after cessation of treatment with both doses of terbutaline were significantly different from the 82 h values (p < 0.05). The decrease in FEV1 was significantly greater after the last terbutaline and placebo inhalation in the placebo group compared with the budesonide treatment group (p = 0.02). We conclude that cessation of regular treatment after 2 wk with both low-dose and high-dose inhaled terbutaline does not result in a significant rebound airway responsiveness in patients with mild asthma. However, the results suggest a small rebound bronchoconstriction that does not occur when asthmatic patients are also treated with budesonide.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1073-449X
pubmed:author
pubmed:issnType
Print
pubmed:volume
153
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
70-5
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:8542165-Administration, Inhalation, pubmed-meshheading:8542165-Administration, Topical, pubmed-meshheading:8542165-Adolescent, pubmed-meshheading:8542165-Adrenergic beta-Agonists, pubmed-meshheading:8542165-Adult, pubmed-meshheading:8542165-Aerosols, pubmed-meshheading:8542165-Anti-Inflammatory Agents, pubmed-meshheading:8542165-Asthma, pubmed-meshheading:8542165-Bronchial Provocation Tests, pubmed-meshheading:8542165-Bronchodilator Agents, pubmed-meshheading:8542165-Budesonide, pubmed-meshheading:8542165-Double-Blind Method, pubmed-meshheading:8542165-Female, pubmed-meshheading:8542165-Forced Expiratory Volume, pubmed-meshheading:8542165-Glucocorticoids, pubmed-meshheading:8542165-Humans, pubmed-meshheading:8542165-Ipratropium, pubmed-meshheading:8542165-Male, pubmed-meshheading:8542165-Methacholine Chloride, pubmed-meshheading:8542165-Middle Aged, pubmed-meshheading:8542165-Placebos, pubmed-meshheading:8542165-Pregnenediones, pubmed-meshheading:8542165-Terbutaline, pubmed-meshheading:8542165-Time Factors
pubmed:year
1996
pubmed:articleTitle
Rebound airway obstruction and responsiveness after cessation of terbutaline: effects of budesonide.
pubmed:affiliation
Department of Pulmonology, University Hospital Groningen, The Netherlands.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Controlled Clinical Trial, Research Support, Non-U.S. Gov't